Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Stereotaxis, Inc. (STXS)
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$0.96+13.55%
Close 2026-11-04 · 1-day change
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for STXS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce losses and improve earnings | A supporting condition in Stereotaxis, Inc.'s published investment case. The stated target is EPS loss narrows toward -$0.13 or better by FY27. | Improving | EPS loss worsens or stays below -$0.19 in FY26 | Diluted EPS: $-0.05 per share FY2026-Q2; GAAP. Published target: EPS loss narrows toward -$0.13 or better by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-0.05 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
STXS is a speculative growth business, not yet a proven profitable compounder. Its long-term thesis remains intact, while recent results are neutral and the company remains loss-making.
Valuation is expensive versus peers, and the expectations gap is negative, meaning expectations appear demanding relative to the evidence. The snapshot labels pricing as justified and reports no fragility gates, but confidence is medium.
Near-term, revenue has grown from $6.3 million in the first quarter of 2026 to $7.7 million in the second, and management expects more than $40 million for the year. Robotic catheter revenue topped $1 million in the second quarter, while the manufacturing ramp and early product sales are progressing; integration of Robocath remains ongoing. Execution risk is high, with consecutive earnings misses and a meaningful chance of another miss noted in the snapshot.
Over the next few quarters, the thesis hinges on meeting the 2026 growth goal and converting manufacturing capacity and early product adoption into sustained revenue. A guidance cut would be a meaningful negative, while continued earnings strength from healthcare sector leaders could support the sector backdrop. Weaker jobs data could also raise recession concerns and weigh on cyclical healthcare names.
For the next one to three years, STXS offers a growth thesis supported by product adoption and a favorable sector backdrop, but it is loss-making, expensive versus peers, and exposed to execution and earnings risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Revenue exceeds $10 million in Q3 and Q4 2026 | A primary condition in Stereotaxis, Inc.'s published investment case. The stated target is >= $10 million revenue each in Q3 and Q4 2026. | Broken | Revenue falls below $10 million in either Q3 or Q4 2026 | Revenue: $7.67M FY2026-Q2; GAAP. Published target: >= $10 million revenue each in Q3 and Q4 2026. Target period is not explicitly aligned with this observation. Aug 12, 20267,670,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve double-digit revenue growth in 2026 | Stereotaxis aims for double-digit revenue growth in 2026. | Broken | YoY revenue growth falls below 8% in FY26 | Revenue growth: -12.82% FY2026-Q2; GAAP. Published target: >=10% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-12.821096 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.13 → $-0.15 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-07-25 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-07-26 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-07-27 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-07-28 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-07-29 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-07-30 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-07-31 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-01 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-02 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-03 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-04 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-05 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-06 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-08 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-09 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-10 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-12 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-13 | $-0.13 | $53,275,000 | 3 / 4 |
| 2026-08-14 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-15 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-16 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-17 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-18 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-19 | $-0.13 | $53,000,000 | 2 / 3 |
| 2026-08-20 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-21 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-22 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-23 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-24 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-25 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-26 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-27 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-28 | $-0.15 | $47,666,667 | 2 / 2 |
| 2026-08-29 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-08-30 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-08-31 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-01 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-02 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-03 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-04 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-05 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-06 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-07 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-08 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-09 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-10 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-11 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-12 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-13 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-14 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-15 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-16 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-17 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-18 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-19 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-20 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-21 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-22 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-23 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-24 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-25 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-26 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-27 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-28 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-29 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-09-30 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-01 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-02 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-03 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-04 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-05 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-06 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-07 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-08 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-09 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-10 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-11 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-12 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-13 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-14 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-15 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-16 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-17 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-18 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-19 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-20 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-21 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-22 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-23 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-24 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-25 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-26 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-27 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-28 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-29 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-30 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-10-31 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-11-01 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-11-02 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-11-03 | $-0.15 | $45,666,667 | 2 / 2 |
| 2026-11-04 | $-0.15 | $45,666,667 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.